How AI is transforming the biopharma industry

The AI buzz is everywhere. It's the hot topic of every conference, every panel, every strategy deck. But beyond the talk, how much real progress is being made with AI in pharma?Who’s actually using it? And how? Digitalya OPS’s latest report cuts through the noise to reveal where the industry truly stands on AI today, drawing on insights from over 200 leaders across the EU, US, and Asia.Inside, you’ll find: - Clear perspectives on AI adoption across the sector - Where top companies are placing their biggest bets - The key trends shaping AI’s next phase, and how to stay ahead I was grateful to be asked to share my perspective for the report and it’s great to see such an honest snapshot of where the industry is now, and where it’s heading next. Download link below 👇 https://lnkd.in/e-_E6QsF

Looking past all the talk, where exactly does pharma now stand on AI? Everyone says they're using it, but are they? And how? Digitalya OPS's latest report explores the latest industry position on AI, featuring insights from 200+ leaders across the EU, US, and Asia. Inside, you'll find: - Perspectives on AI adoption across the industry - Where top companies are making strategic investments - A clear roadmap to success with the key trends defining AI's next phase Download it below 👇 https://lnkd.in/eYYcGeWX

💬 AI is transforming pharma- not just in R&D or patient care, but across the entire supply chain. Where do you see the biggest opportunities for AI to make an impact? I’ve learned that curiosity doesn’t always need a reason, sometimes it’s just about exploring what sparks your interest. I recently explored “How AI is Transforming Pharma: From R&D to Care Delivery” on LinkedIn Learning, and it opened my eyes to how data and AI are reshaping not only discovery and clinical development, but also the way medicines ultimately reach patients. It’s fascinating to see how technology is bridging the gap between research and real-world outcomes, turning insights into impact. For me, learning like this is about staying curious, tech-driven, and ready to adapt as the industry continues to evolve. Here’s to curiosity, growth, and being open to what’s next. 🌿 #AIinPharma #PharmaSupplyChain #ContinuousLearning #Curiosity #TechDriven #LifelongLearning #DigitalTransformation How AI Is Transforming Pharma: From R&D to Care Delivery" by Emily Lewis! Check it out: https://lnkd.in/dYf6H88S #artificialintelligenceforbusiness, #healthcare, #artificialintelligence, #pharmaceutics.

With the proliferation of AI-driven tools, how do you apply new technologies effectively to accelerate drug development? Atropos Health’s Vinny Marino joins Tarun Walia of Novo Nordisk to answer this question and more during a presentation at the 13th Annual IMPACCT Real-World Evidence Summit in Boston next week, October 28-29. In this session, you’ll learn more about: 📈 Leveraging AI/ML to spot and integrate high-value RWE opportunities 💻 How LLMs can transform complex RWD into actionable evidence 📊 Proven methods to evaluate data quality and source reliable RWE Register to attend: https://hubs.li/Q03PHL3y0 #AtroposHealth #RWE #RealWorldEvidence #DrugDevelopment #AIinPharma #Pharma #LifeSciences #ArtificialIntelligence #AI #MachineLearning #LLMs #RWD #RealWorldData #EvidenceGeneration #DigitalHealth

Just read the WHO's latest on AI in medicine development, and it got me thinking 🤔 The report highlights how AI is touching nearly EVERY stage of pharmaceutical development now. Amazing potential, but they're rightly flagging the governance challenges. It reminds me of what we're seeing across all industries - AI tools racing ahead while the rulebooks struggle to keep up. In my world of building AI agent solutions, we face the same tension daily: maximising capability while ensuring proper guardrails are in place. The WHO paper emphasises something I've been banging on about for ages - AI needs to deliver public benefit, not just commercial advantage. Who else is navigating these AI governance challenges in their sector? Any practical approaches you've found that work? Drop me a DM if you're wrestling with similar issues in your tech stack - always happy to share notes on what's working (and what definitely isn't! 😅). #AIGovernance #TechEthics #AIInHealthcare https://lnkd.in/dWqd8idE

In drug design, AI is no longer just an accelerator; it’s about to become the new standard. The collaboration between Nabla Bio and Takeda tells us that the next revolution may come from algorithms replacing trial and error. The key is not who is the first to put up the model, but who is the first to close the loop between the model and human body data. https://lnkd.in/eMwWS97Y

Agentic AI is opening up a new era for pharma, with autonomous systems streamlining drug discovery, clinical trials, and manufacturing. While these advancements promise efficiency and innovation, they require robust validation, transparent processes, and regulatory compliance to build stakeholder trust. Learn more here. #Pharma #AI #AIAgents #PharmaTech #Innovation

Had the pleasure of learning more about NetraMark AI today and how AI is reshaping the future of clinical trials. In my latest episode of The MidDay Bell, I sit down with George Achilleos, CEO of NetraMark (CSE: AIAI | OTCQB: AINMF | FSE: PF0), and Dr. Luca Pani, Chief Innovation & Regulatory Officer — formerly Director General of Italy’s Medicines Agency and advisor to the EMA. We discuss how "Explainable AI" can help pharmaceutical companies design smarter, faster, and more successful studies — reducing failure rates and saving hundreds of millions in R&D costs. 🎯 Key topics: • How AI identifies patient “personas” to improve drug-trial outcomes • Why explainability matters for regulators like the FDA and EMA • Their collaboration with NIMH and the upcoming FDA Critical Path Innovation Meeting • What this means for investors as NetraMark enters its commercialization phase 🎥 Watch the full interview → https://lnkd.in/g_cs9eep #AI #Biotech #ClinicalTrials #PharmaInnovation #DrugDiscovery #ExplainableAI #MidDayBell #NetraMark #Investing

The 2025 Pistoia Alliance Lab of the Future Survey data reveals that 77% of labs are investing in AI, but the biggest obstacle is an 'AI Skills Gap,'. The real challenge is building the people and skills to make AI adoption stick. The industry's focus is shifting from simple efficiency to accelerating innovation and new breakthroughs. They need next-generation, intuitive, data-first tools that close the skills gap and unlock discovery. Read the article here: https://lnkd.in/en7ZSwBX That’s why events like London Lab Live, Future Labs Live Basel and Future Labs Live USA are so important. It’s where innovation meets implementation. #FutureLabsLive #AI #LabAutomation #LifeSciences #Startups #Innovation #DigitalTransformation #LabTech